Certe Medische Diagnostiek en Advies Stichting
Certe Medische Diagnostiek en Advies Stichting is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Efficacy, safety, and pharmacokinetics of NNC0519-0130 once weekly s.c. versus semaglutide 1.0 mg and placebo in people with chronic kidney disease, with or without type 2 diabetes, and with overweight or obesity: a proof-of-concept and dose-finding study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
Sponsor Inhibikase Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
Efficacy and tolerability of tasipimidine after 3 repeated bed-time doses in patients with insomnia disorder with a 4-week extension part
Sponsor Orion Corporation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Protocol Amendment 2 extended the trial period and increased the number of sites.
- Protocol Amendment 4 extended Part 2 treatment from 3 days in a sleep laboratory to a 4-week period in the sleep laboratory and at home.
- Part 3 was not started because the interim analysis of Parts 1 and 2 showed no significant primary-endpoint efficacy for any tasipimidine dose versus placebo.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
Sponsor Crystalys Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® IM versus Placebo IM as an Enhancer Adjunctive to Antidepressant Treatment in Major Depression Disorder Patients Who have not Experienced Sufficient Symptoms Improvement Despite Antidepressant Treatment
Sponsor Mylan Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Antidepressant Treatment in Patients with Major Depression Disorder with Mild to Moderate Symptoms
Sponsor Mylan Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients with Moderate to Severe Rheumatoid Arthritis.
Sponsor Mabxience Research S.L.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Certe Medische Diagnostiek en Advies Stichting?
The 2026-10-09 snapshot links Certe Medische Diagnostiek en Advies Stichting to 11 distinct CTIS trials. Recorded services include Laboratory services, Anti-CCP and HIV testing, HIV confirmatory testing, Specialty Lab – Vitamin : +31634205226, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Certe Medische Diagnostiek en Advies Stichting?
The most frequently recorded therapeutic areas are Endocrinology, Immunology, Cardiology, Gynecology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Certe Medische Diagnostiek en Advies Stichting conducted?
The linked trials record locations in 19 countries, including Poland, Spain, Italy, Germany, Belgium. These are trial locations, not confirmed office locations or countries where Certe Medische Diagnostiek en Advies Stichting delivered services.
What can this page tell me about Certe Medische Diagnostiek en Advies Stichting's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Certe Medische Diagnostiek en Advies Stichting. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Certe Medische Diagnostiek en Advies Stichting